NeuroLaunch

NeuroLaunch sources deal flow via its proprietary accelerator program, which surfaces early-stage neuroscience and neurotechnology startups. Applicants enter a structured program that provides mentoring and connects them to the firm's network of research institutions and investors. This model generates a pipeline of ventures that are then considered for direct investment, with the program culminating in a Demo Day.

NeuroLaunch functions primarily as an accelerator with a direct investment mandate, not as a traditional closed-end fund. The firm invests in and facilitates growth for early-stage brain technology ventures through its program cohorts. This hybrid posture mixes a community-driven accelerator model with principal investment activity at the seed and start-up stages.

NeuroLaunch targets the earliest stages of company formation, focusing on seed and start-up ventures. The firm has also indicated an ability to participate in growth-stage rounds and to provide venture debt. However, the core of its activity is centered on performing diligence and making initial investments through its own accelerator pipeline.

NeuroLaunch focuses on ventures applying technology to the brain and nervous system. This encompasses brain-computer interfaces, AI/ML applications for neurological conditions, and digital health tools for monitoring and improving brain function. The firm's thesis is that the brain technology frontier represents a distinct and high-growth sector requiring a specialized investment community.

NeuroLaunch's Demo Day is the capstone event of its accelerator program, showcasing portfolio companies to a curated audience of investors. It serves as the primary mechanism for its ventures to secure follow-on funding and for the firm to connect its community with external capital partners. The event reinforces the firm's dual role as both company builder and investor.